Search Result

Results for "

Anticonvulsant effect

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Apoptosis (3) Bacterial (1) Biochemical Assay Reagents (1) Calcium Channel (2) Caspase (2) Drug Derivative (3) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (2) EGFR (1) Endogenous Metabolite (4) ERK (2) GABA Receptor (10) Guanylate Cyclase (1) iGluR (14) Imidazoline Receptor (3) Interleukin Related (1) Isotope-Labeled Compounds (3) Leukotriene Receptor (1) mGluR (2) Monoamine Oxidase (5) nAChR (3) Neuropeptide Y Receptor (2) NF-κB (1) Opioid Receptor (3) P-glycoprotein (2) p38 MAPK (1) PAK (1) PARP (2) PGE synthase (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (3) Reactive Oxygen Species (ROS) (2) Reference Standards (6) Sodium Channel (2) Somatostatin Receptor (1) Thyroid Hormone Receptor (1) TNF Receptor (1) UGT (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (9) Infection (3) Inflammation/Immunology (10) Metabolic Disease (1) Neurological Disease (47)

By Targets:

Adrenergic Receptor (3)

Apoptosis (3)

Bacterial (1)

Biochemical Assay Reagents (1)

Calcium Channel (2)

Caspase (2)

Drug Derivative (3)

Drug Intermediate (1)

Drug Isomer (1)

Drug Metabolite (2)

EGFR (1)

Endogenous Metabolite (4)

ERK (2)

GABA Receptor (10)

Guanylate Cyclase (1)

iGluR (14)

Imidazoline Receptor (3)

Interleukin Related (1)

Isotope-Labeled Compounds (3)

Leukotriene Receptor (1)

mGluR (2)

Monoamine Oxidase (5)

nAChR (3)

Neuropeptide Y Receptor (2)

NF-κB (1)

Opioid Receptor (3)

P-glycoprotein (2)

p38 MAPK (1)

PAK (1)

PARP (2)

PGE synthase (1)

Platelet-activating Factor Receptor (PAFR) (1)

Potassium Channel (3)

Reactive Oxygen Species (ROS) (2)

Reference Standards (6)

Sodium Channel (2)

Somatostatin Receptor (1)

Thyroid Hormone Receptor (1)

TNF Receptor (1)

UGT (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (9)

Infection (3)

Inflammation/Immunology (10)

Metabolic Disease (1)

Neurological Disease (47)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101392

Harmane 1 Publications Verification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor	Neurological Disease Inflammation/Immunology
Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-B0184

Felbamate 2 Publications Verification W-554; ADD-03055	iGluR	Neurological Disease
Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-B1302

Quinidine hydrochloride monohydrate Maximum Cited Publications 25 Publications Verification	P-glycoprotein PARP Caspase Apoptosis Potassium Channel	Cardiovascular Disease Neurological Disease
Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on I_K(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .

HY-W090292

Olivetolic acid	Drug Intermediate	Neurological Disease
Olivetolic acid is a biosynthetic precursor of cannabinol acid (CBGA). Olivetolic acid exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Olivetolic acid can be used for the study of convulsion .

HY-B1199

Nialamide	Monoamine Oxidase Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Nialamide is a non-selective monoamine oxidase (MAO) inhibitor. Nialamide inhibits MAO and regulates ROS production. Nialamide induces hyperkinesis in animals, enhances the anticonvulsant effect of Diphenylhydantoin in mice, increases rectal temperature, and enhances the pressor effect of Norepinephrine. Nialamide can be used in the research of depression, inflammatory diseases, neurodegenerative diseases, and hypertension .

HY-103234A

GYKI 52466 dihydrochloride	iGluR	Neurological Disease
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .

HY-P3960

(Glu2)-TRH	Thyroid Hormone Receptor Endogenous Metabolite	Neurological Disease
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS .

HY-103230

IEM-1460	iGluR	Neurological Disease
IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo .

HY-136591

Demoxepam	Drug Metabolite	Neurological Disease Cancer
Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [ ³H]tryptophan binding to rat hepatic nuclei .

HY-N8303

Gardenin A	ERK PAK	Neurological Disease Inflammation/Immunology
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .

HY-123335A

L-796778 acetate	Somatostatin Receptor	Neurological Disease
L-796778 acetate is a selective agonist of the sst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 acetate is a partial agonist that inhibits Forskolin (HY-15371)-stimulated cAMP production with an IC₅₀ value of 18 nM. L-796778 acetate has anticonvulsant effect .

HY-103506

NNC-711 NO-711 hydrochloride	GABA Receptor	Neurological Disease
NNC-711 (NO-711 hydrochloride) is a potent and selective inhibitor of GAT-1 (GABA transporter 1) with IC₅₀ values of 0.04, 0.38, 171, 1700, 349, 622 μM for human GAT-1, rat GAT-1, rGAT-2, hGAT-3, rGAT-3, hBGT-3, respectively. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity .

HY-101392A

Harmane hydrochloride 1 Publications Verification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor	Neurological Disease Inflammation/Immunology
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-P1132A

Galanin (1-29)(rat, mouse) TFA	Neuropeptide Y Receptor	Neurological Disease
Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with K_is of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect .

HY-141795

Posovolone Co 134444	Drug Derivative	Neurological Disease
Posovolone (Co 134444) is an orally active, neuroactive steroid. Posovolone has anticonvulsant and anxiolytic-like activity as well as ataxic effects .

HY-N4267

Yangambin	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-P1132

Galanin (1-29)(rat, mouse)	Neuropeptide Y Receptor	Neurological Disease
Galanin (1-29)(rat, mouse) is a non-selective galanin receptor agonist, with K_is of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3 respectively. Anticonvulsant effect .

HY-116944

Ro 17-1812	GABA Receptor	Neurological Disease
Ro 17-1812 is a benzodiazepine receptor partial agonist with anticonvulsant effect .

HY-B0184A

Felbamate hydrate W-554 hydrate; ADD-03055 hydrate	iGluR	Neurological Disease
Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

HY-177986

NCR 631	Drug Derivative	Neurological Disease
NCR 631 is a 3-HAO inhibitor and 3-hydroxyanthranilic acid (HY-W001171) analogue. NCR-631 has anticonvulsant properties. NCR-631shows a concentration-dependent protective effect against the anoxia .

HY-W013378S

Carbamazepine 10,11 epoxide-d2	Endogenous Metabolite Isotope-Labeled Compounds	Others
Carbamazepine 10,11 epoxide-d₂ is the deuterium labeled Carbamazepine 10,11 epoxide . Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-176065

Nav1.2-IN-1	Sodium Channel	Neurological Disease
Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective Nav1.2 inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC₅₀ value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode .

HY-133773

Desoxochlordiazepoxide	Biochemical Assay Reagents	Neurological Disease
Desoxochlordiazepoxide is a kind of benzodiazepine compound. Desoxochlordiazepoxide has anticonvulsant effect .

HY-125555

Azosulfamide	Bacterial	Infection Neurological Disease
Azosulfamide has an anticonvulsant effect and can be used for research of epilepsy. Azosulfamide is active against recurrent tetanus .

HY-U00315S

Gidazepam-d5 Gidasepam-d₅; Hidazepam-d₅; Hydazepam-d₅	GABA Receptor	Neurological Disease
Gidazepam-d5 is a deuterium labeled Gidazepam. Gidazepam is an agonist of GABA receptor channels (GABA RCs), and has anticonvulsant effect .

HY-107323

Bentazepam QM 6008; Thiadipone; Tiadipone	GABA Receptor	Neurological Disease
Bentazepam (Thiadipone) is a compound with short-action anxiolytic effect. Bentazepam shows anticonvulsant and sedative properties. Bentazepam can be used for the research of depressive disorder and anxiety .

HY-107323A

Bentazepam hydrochloride QM 6008 hydrochloride; Thiadipone hydrochloride; Tiadipone hydrochloride	GABA Receptor	Neurological Disease
Bentazepam (QM 6008, Thiadipone) hydrocholide is a compound with short-action anxiolytic effect. Bentazepam hydrocholide shows anticonvulsant and sedative properties. Bentazepam hydrocholide can be used for the research of depressive disorder and anxiety .

HY-B0184S1

Felbamate-d5 Felbamyl-d₅; Felbatol-d₅; Taloxa-d₅	iGluR	Neurological Disease
Felbamate-d₅ is the deuterium labeled Felbamate . Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

HY-B0184R

Felbamate (Standard) W-554 (Standard); ADD-03055 (Standard)	Reference Standards iGluR	Neurological Disease
Felbamate (Standard) is the analytical standard of Felbamate. This product is intended for research and analytical applications. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-B1199A

Nialamide hydrochloride	Monoamine Oxidase Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Nialamide hydrochloride is a non-selective monoamine oxidase (MAO) inhibitor. Nialamide hydrochloride inhibits MAO and regulates ROS production. Nialamide hydrochloride induces hyperkinesis in animals, enhances the anticonvulsant effect of Diphenylhydantoin in mice, increases rectal temperature, and enhances the pressor effect of Norepinephrine. Nialamide hydrochloride can be used in the research of depression, inflammatory diseases, neurodegenerative diseases, and hypertension .

HY-B0184S

Felbamate-d4	iGluR	Neurological Disease
Felbamate-d₄ (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-W097106

(S)-3-N-Cbz-Amino-succinimide	Drug Isomer	Neurological Disease
(S)-3-N-Cbz-Amino-succinimide (Compound 1d) is an antiepileptic agent that can inhibit pentylenetetrazole (PTZ) and maximal electroshock (MES)-induced tonic convulsions in mice .

HY-147377

N-Salicyloyltryptamine	Calcium Channel ERK Potassium Channel Guanylate Cyclase NF-κB	Cardiovascular Disease Neurological Disease Inflammation/Immunology
N-Salicyloyltryptamine acts on voltage-dependent Na ⁺, Ca ²⁺, and K ⁺ ion channels inhibitor. N-Salicyloyltryptamine inhibits K ⁺ currents with an IC₅₀ value of 34.6 μM (I_to). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect ^- .

HY-103234

GYKI 52466	iGluR	Neurological Disease
GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .

HY-103234B

GYKI 52466 hydrochloride	iGluR	Neurological Disease
GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .

HY-177302

mGluR2 modulator 6	mGluR	Neurological Disease
mGluR2 modulator 6 (Compound 25-a) is a mGluR2 modulator. mGluR2 modulator 6 has anticonvulsant activity in the 6Hz epilepsy model, and the effect is better when combined with Levetiracetam (HY-B0106). mGluR2 modulator 6 can be used in the research of epilepsy .

HY-103234AR

GYKI 52466 dihydrochloride (Standard)	Reference Standards iGluR	Neurological Disease
GYKI 52466 (dihydrochloride) (Standard) is the analytical standard of GYKI 52466 (dihydrochloride). This product is intended for research and analytical applications. GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .

HY-W013378S2

Carbamazepine 10,11-epoxide-13C,d2	Endogenous Metabolite	Others
Carbamazepine 10,11-epoxide- ¹³C,d₂ is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a ¹³C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-17032

Indeloxazine (rac)-AS1069562 free base; YM-08054 free base	Endogenous Metabolite	Neurological Disease
Indeloxazine ((rac)-AS1069562 free base) is a brain active compound with anti-amnesic activity. Indeloxazine significantly prolonged the step latency in senescence accelerated mice (SAM-P/8/Ta), indicating that it has a promoting effect on brain function. Indeloxazine has a broader pharmacology than piracetam and exhibits stronger anti-amnesic activity. Indeloxazine has also been used as an anticonvulsant compound, further supporting its potential use in neuroprotection and behavioral improvement .

HY-W777360

Harman-13C2,15N	Isotope-Labeled Compounds Adrenergic Receptor Monoamine Oxidase nAChR Opioid Receptor Imidazoline Receptor GABA Receptor	Neurological Disease Inflammation/Immunology
Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-105340

MDL 27266	iGluR	Neurological Disease
MDL 27266 is an orally active NMDA receptor antagonist with neuroprotective effect. MDL 27266 is a broad-spectrum anticonvulsant agent .

HY-103230R

IEM-1460 (Standard)	Reference Standards iGluR	Neurological Disease
IEM-1460 (Standard) is the analytical standard of IEM-1460 (HY-103230). This product is intended for research and analytical applications. IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo .

HY-182548

BTS 72664	GABA Receptor Sodium Channel iGluR	Cardiovascular Disease Neurological Disease
BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABA_A receptor (GABA_A receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na ⁺ channels (K_i = 350 μM) and NMDA receptors (NMDA receptor) (IC₅₀ = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine .

HY-136591R

Demoxepam (Standard)	Drug Metabolite Reference Standards	Neurological Disease Cancer
Demoxepam (Standard) is the analytical standard of Demoxepam. This product is intended for research and analytical applications. Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [ ³H]tryptophan binding to rat hepatic nuclei .

HY-N16538

4-(Acetoxymethyl)phenyl glucoside	Drug Derivative	Cardiovascular Disease Neurological Disease
4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .

HY-103566R

LY456236 (Standard)	Reference Standards mGluR EGFR p38 MAPK Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
LY456236 (Standard) is the analytical standard of LY456236 (HY-103566). This product is intended for research and analytical applications. LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC₅₀ of 0.145 μM. LY456236 can also inhibit EGFR, with an IC₅₀ of 0.918 μM. LY456236 has anticonvulsant effects and blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research .

HY-W115674

Quinidine hydrochloride	P-glycoprotein PARP Caspase Apoptosis Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Quinidine hydrochloride is an orally active antiarrhythmic agent. Quinidine hydrochloride reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride exerts sustained block and open-channel block effects on I_K(f). Quinidine hydrochloride alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride can be used in studies related to uterine sarcoma and seizures .

HY-15080

GYKI 53405 LY 293606	iGluR	Cardiovascular Disease Neurological Disease
GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABA_A, GABA_B or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .

HY-103506R

NNC-711 (Standard) NO-711 hydrochloride (Standard)	Reference Standards GABA Receptor	Neurological Disease
NNC-711 (Standard) is the analytical standard of NNC-711 (HY-103506). This product is intended for research and analytical applications. NNC-711 (NO-711 hydrochloride) is a potent and selective inhibitor of GAT-1 (GABA transporter 1) with IC₅₀ values of 0.04, 0.38, 171, 1700, 349, 622 μM for human GAT-1, rat GAT-1, rGAT-2, hGAT-3, rGAT-3, hBGT-3, respectively. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity .

HY-W700834

Harman-d3	Isotope-Labeled Compounds	Neurological Disease Inflammation/Immunology
Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Product Name	Target	Research Area

HY-P3960

(Glu2)-TRH	Thyroid Hormone Receptor Endogenous Metabolite	Neurological Disease
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS .

HY-P1132A

Galanin (1-29)(rat, mouse) TFA	Neuropeptide Y Receptor	Neurological Disease
Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with K_is of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-101392

Harmane 1 Publications Verification	Alkaloids other families Pyridine Alkaloids Plants Indole Alkaloids Source Classification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-B1302

Quinidine hydrochloride monohydrate Maximum Cited Publications 25 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Rubiaceae Cinchona calisaya Wedd. Plants Disease Research Fields Source Classification	P-glycoprotein PARP Caspase Apoptosis Potassium Channel
Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on I_K(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .

HY-P3960

(Glu2)-TRH	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Thyroid Hormone Receptor Endogenous Metabolite
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS .

HY-N8303

Gardenin A	Flavonoids Flavones Rutaceae Plants Citrus reticulata Blanco Source Classification	ERK PAK
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .

HY-101392A

Harmane hydrochloride 1 Publications Verification	Apocynaceae Alkaloids Other Alkaloids Plants Rauwolfia canescens Source Classification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-N4267

Yangambin	Cardiovascular Disease Structural Classification other families Classification of Application Fields Lignans Phenylpropanoids Plants Disease Research Fields Source Classification	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-N16538

4-(Acetoxymethyl)phenyl glucoside	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Drug Derivative
4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .

Cat. No.	Product Name	Chemical Structure

HY-W013378S

Carbamazepine 10,11 epoxide-d2
Carbamazepine 10,11 epoxide-d₂ is the deuterium labeled Carbamazepine 10,11 epoxide . Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-U00315S

Gidazepam-d5
Gidazepam-d5 is a deuterium labeled Gidazepam. Gidazepam is an agonist of GABA receptor channels (GABA RCs), and has anticonvulsant effect .

HY-B0184S1

Felbamate-d5
Felbamate-d₅ is the deuterium labeled Felbamate . Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

HY-B0184S

Felbamate-d4
Felbamate-d₄ (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-W013378S2

Carbamazepine 10,11-epoxide-13C,d2
Carbamazepine 10,11-epoxide- ¹³C,d₂ is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a ¹³C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-W777360

Harman-13C2,15N

Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-W700834

Harman-d3

Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Anticonvulsant effect

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products